deltatrials
Terminated PHASE2 INTERVENTIONAL 1-arm NCT01921296

Pilot Study of Cyclobenzaprine for Treatment of Sleep Disturbance in Aromatase Inhibitor-treated Breast Cancer Patients

UMCC 2013.051: Prospective Pilot Study Evaluating the Use of Cyclobenzaprine for Treatment of Sleep Disturbance, Fatigue, and Musculoskeletal Symptoms in Aromatase Inhibitor-treated Breast Cancer Patients

Sponsor: Damon Runyon Cancer Research Foundation

Conditions Pain Sleep Initiation and Maintenance Disorders
Interventions Cyclobenzaprine
Updated 10 times since 2017 Last updated: Mar 21, 2016 Started: Aug 31, 2013 Primary completion: May 31, 2014 Completion: Apr 30, 2015
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Accrual terminated early because of poor accrual

Other Pain trials with similar outcome

Browse all Pain trials

This PHASE2 trial investigates Pain and Sleep Initiation and Maintenance Disorders and is currently terminated or withdrawn. Damon Runyon Cancer Research Foundation leads this study, which shows 10 recorded versions since 2013 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshotTerminated~Feb 2017 – ~Jun 2018 · 16 months · monthly snapshotTerminated~Jun 2018 – ~Feb 2019 · 8 months · monthly snapshotTerminated~Feb 2019 – ~Jan 2021 · 23 months · monthly snapshotTerminated~Jan 2021 – ~Dec 2021 · 11 months · monthly snapshotTerminated~Dec 2021 – ~Dec 2022 · 12 months · monthly snapshotTerminated~Dec 2022 – ~Jan 2023 · 31 days · monthly snapshotTerminated~Jan 2023 – ~Jul 2024 · 18 months · monthly snapshotTerminated~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotTerminated~Sep 2024 – present · 24 months · monthly snapshotTerminated

Change History

10 versions recorded

  1. Sep 2024 — Present [monthly]

    Terminated PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE2

  3. Jan 2023 — Jul 2024 [monthly]

    Terminated PHASE2

  4. Dec 2022 — Jan 2023 [monthly]

    Terminated PHASE2

  5. Dec 2021 — Dec 2022 [monthly]

    Terminated PHASE2

▶ Show 5 earlier versions

  1. Jan 2021 — Dec 2021 [monthly]

    Terminated PHASE2

  2. Feb 2019 — Jan 2021 [monthly]

    Terminated PHASE2

  3. Jun 2018 — Feb 2019 [monthly]

    Terminated PHASE2

  4. Feb 2017 — Jun 2018 [monthly]

    Terminated PHASE2

  5. Jan 2017 — Feb 2017 [monthly]

    Terminated PHASE2

    First recorded

Aug 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Damon Runyon Cancer Research Foundation
  • Lynn Henry
Data source: University of Michigan Rogel Cancer Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations